Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (59)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (1)
Diagnostics guidance (2)
Health technology evaluations (1)
Interventional procedures guidance (3)
NICE guidelines (1)
Technology appraisal guidance (59)
Apply filters
Showing 1 to 50 of 59
Sort by
Date
Title
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Selpercatinib for untreated RET fusion-positive advanced non-small-cell
lung cancer
TA911
26 July 2023
26 July 2023
Lorlatinib for untreated ALK-positive advanced non-small-cell
lung cancer
TA909
12 July 2023
12 July 2023
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell
lung cancer
TA898
14 June 2023
14 June 2023
Capmatinib for treating advanced non-small-cell
lung cancer
with MET exon 14 skipping (terminated appraisal)
TA884
3 May 2023
3 May 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell
lung cancer
TA876
22 March 2023
22 March 2023
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell
lung cancer
after platinum-based chemotherapy
TA850
14 December 2022
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell
lung cancer
(terminated appraisal)
TA848
1 December 2022
1 December 2022
Atezolizumab for adjuvant treatment of resected non-small-cell
lung cancer
TA823
28 September 2022
28 September 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell
lung cancer
TA812
3 August 2022
3 August 2022
Durvalumab for maintenance treatment of unresectable non-small-cell
lung cancer
after platinum-based chemoradiation
TA798
22 June 2022
22 June 2022
Tepotinib for treating advanced non-small-cell
lung cancer
with MET gene alterations
TA789
18 May 2022
18 May 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell
lung cancer
TA781
30 March 2022
30 March 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell
lung cancer
TA770
9 February 2022
9 February 2022
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell
lung cancer
after complete tumour resection
TA761
19 January 2022
19 January 2022
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell
lung cancer
TA760
12 January 2022
12 January 2022
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell
lung cancer
TA724
8 September 2021
8 September 2021
Nivolumab for advanced non-squamous non-small-cell
lung cancer
after chemotherapy
TA713
7 July 2021
7 July 2021
Atezolizumab monotherapy for untreated advanced non-small-cell
lung cancer
TA705
2 June 2021
2 June 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell
lung cancer
TA683
10 March 2021
10 March 2021
Brigatinib for ALK-positive advanced non-small-cell
lung cancer
that has not been previously treated with an ALK inhibitor
TA670
27 January 2021
27 January 2021
Durvalumab in combination for untreated extensive-stage small-cell
lung cancer
(terminated appraisal)
TA662
25 November 2020
25 November 2020
Nivolumab for advanced squamous non-small-cell
lung cancer
after chemotherapy
TA655
21 October 2020
21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell
lung cancer
TA653
14 October 2020
14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell
lung cancer
TA654
14 October 2020
14 October 2020
Entrectinib for treating ROS1-positive advanced non-small-cell
lung cancer
TA643
12 August 2020
12 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell
lung cancer
TA638
1 July 2020
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell
lung cancer
(terminated appraisal)
TA635
30 June 2020
30 June 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell
lung cancer
TA628
13 May 2020
13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell
lung cancer
(terminated appraisal)
TA618
15 January 2020
15 January 2020
Dacomitinib for untreated EGFR mutation-positive non-small-cell
lung cancer
TA595
14 August 2019
14 August 2019
Atezolizumab in combination for treating metastatic non-squamous non-small-cell
lung cancer
TA584
5 June 2019
5 June 2019
Brigatinib for treating ALK-positive advanced non-small-cell
lung cancer
after crizotinib
TA571
20 March 2019
20 March 2019
Alectinib for untreated ALK-positive advanced non-small-cell
lung cancer
TA536
8 August 2018
8 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell
lung cancer
TA531
18 July 2018
18 July 2018
Crizotinib for treating ROS1-positive advanced non-small-cell
lung cancer
TA529
4 July 2018
4 July 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell
lung cancer
after chemotherapy
TA520
16 May 2018
16 May 2018
Ceritinib for untreated ALK-positive non-small-cell
lung cancer
TA500
24 January 2018
24 January 2018
Pembrolizumab for treating PD-L1-positive non-small-cell
lung cancer
after chemotherapy
TA428
11 January 2017
12 September 2017
Pemetrexed for the maintenance treatment of non-small-cell
lung cancer
TA190
23 June 2010
10 August 2017
Afatinib for treating advanced squamous non-small-cell
lung cancer
after platinum-based chemotherapy (terminated appraisal)
TA444
24 May 2017
24 May 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell
lung cancer
(terminated appraisal)
TA438
29 March 2017
29 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell
lung cancer
(terminated appraisal)
TA436
22 March 2017
22 March 2017
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell
lung cancer
TA422
21 December 2016
21 December 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell
lung cancer
TA411
28 September 2016
28 September 2016
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell
lung cancer
TA406
28 September 2016
28 September 2016
Pemetrexed maintenance treatment for non-squamous non-small-cell
lung cancer
after pemetrexed and cisplatin
TA402
24 August 2016
24 August 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell
lung cancer
TA403
24 August 2016
24 August 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell
lung cancer
TA395
22 June 2016
22 June 2016
Erlotinib and gefitinib for treating non-small-cell
lung cancer
that has progressed after prior chemotherapy
TA374
16 December 2015
16 December 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell
lung cancer
(terminated appraisal)
TA362
28 October 2015
28 October 2015
Current page
1
2
Page
1
of
2
Next page
Results per page
10
25
50
All
Back to top